Search results for "From ACP Journal Club"
Colonoscopy outreach increased CRC screening more than FIT outreach; both were better than usual care
Those choosing screening tests may need to start considering the feasibility of achieving all related downstream actions as well as sensitivity, false-positive rates, safety, and cost, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2018/01/26/7.htm
26 Jan 2018
In active UC, upadacitinib induced and maintained remission
JAK inhibitors, such as upadacitinib, represent an advance in the management of patients with ulcerative colitis (UC); however, it remains unclear whether the balance of efficacy versus risk favors one drug over the others, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2022/10/28/11.htm
28 Oct 2022
Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease
Given the limitations of this large industry-funded trial, the only definitive conclusion one can draw is that patients on aspirin and rivaroxaban with low risk for bleeding may get a very small benefit from long-term proton-pump inhibitor therapy, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2019/10/25/8.htm
25 Oct 2019
Genotypic resistance–guided and medication-guided therapies did not differ for eradicating refractory H pylori
Patients with Helicobacter pylori infection had similar cure rates with resistance-guided and medication-guided therapy, an unexpected finding, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2019/03/22/6.htm
22 Mar 2019
In reflux-related heartburn unresponsive to PPIs, surgery increased treatment success vs active medical treatment
An ACP Journal Club commentary noted that physicians should not change their practice based on the results of the trial, which are in contrast to the literature and expert opinion, until they are confirmed by studies assessing objective primary end points.
https://gastroenterology.acponline.org/archives/2020/03/27/12.htm
27 Mar 2020
In IBS, a smartphone application for self-managing a FODMAP-lowering diet vs. otilonium bromide reduced symptoms at 8 wk
Delivery of a fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering dietary intervention via an app may help educate patients about diet and augment the clinician-patient relationship, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/08/26/9.htm
26 Aug 2022
Daily aspirin for primary CVD prevention increased risk for major GI bleeding in healthy older adults
While aspirin is not recommended for primary prevention of cardiovascular disease (CVD) in most adults ages 70 years and older, more research is needed to assess its role in select high-risk populations of older adults, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2021/01/22/6.htm
22 Jan 2021
In drug-refractory IBS, group CBT with interoceptive exposure improved symptoms and quality of life at 13 wk
Given the results of this small, randomized trial, a head-to-head comparison of multidisciplinary care versus group cognitive behavioral therapy (CBT) delivered over the internet for patients with irritable bowel syndrome (IBS) is now warranted, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2022/08/26/10.htm
26 Aug 2022
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
The benefits of upadacitinib need to be weighed against individual patients' risk profiles, but the drug is an important step forward in treating Crohn disease, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2023/09/22/9.htm
22 Sep 2023
Any of 4 screening options suggested for screen-naive adults 59 to 70 y with ≥ 3% 15-y risk for colorectal cancer
To balance shared decision making and population health in colorectal cancer screening, as called for in a recent guideline, a viable strategy could include universal, opt-out fecal immunochemical testing starting at age 50 years, a commentary in ACP Journal Club noted.
https://gastroenterology.acponline.org/archives/2020/03/27/11.htm
27 Mar 2020